Literature DB >> 12641659

Cellular profile of cytokine production in a patient with visceral leishmaniasis: gammadelta+ T cells express both type 1 cytokines and interleukin-10.

H Lagler1, M Willheim, F Traunmüller, K Wahl, H Winkler, M Ramharter, W Graninger, S Winkler.   

Abstract

The cytokine profile of CD4+, CD8+ T cells, gammadelta+ T cells and natural killer (NK) cells (CD94+CD3-) was studied in a patient with visceral leishmaniasis (VL). The otherwise healthy, human immunodeficiency virus-negative patient acquired the disease in Tuscany, Italy. Diagnosis was made by demonstration of high concentrations of antibodies against Leishmania antigens in serum. Flow cytometry for the detection of intracellular interferon-gamma (IFN-gamma), interleukin (IL)-2, IL-4, IL-6, IL-10, IL-13 and tumour necrosis factor (TNF)-alpha expression in peripheral blood mononuclear cells stimulated with phorbol 12-myristate 13-acetate and ionomycin was performed, followed by treatment with liposomal amphotericin B. CD4+ cells were identified as major cytokine-expressing cells, capable of producing both type 1 and type 2 cytokines. A high frequency of IL-4- and IL-13-expressing CD8+ cells was noted. NK cells and gammadelta+ T cells, thought to be involved in innate host defences against Leishmania, expressed IFN-gamma and TNF-alpha. Ten per cent of gammadelta+ T cells expressed IL-10, predominantly together with IFN-gamma, suggesting additional immune-regulatory roles for this T-cell subset in VL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12641659     DOI: 10.1046/j.1365-3083.2003.01223.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L De A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; J Van Weyenbergh; R Correa-Oliveira
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

2.  Disparate immunoregulatory potentials for double-negative (CD4- CD8-) alpha beta and gamma delta T cells from human patients with cutaneous leishmaniasis.

Authors:  Lis R V Antonelli; Walderez O Dutra; Ricardo R Oliveira; Karen C L Torres; Luiz H Guimarães; Olivia Bacellar; Kenneth J Gollob
Journal:  Infect Immun       Date:  2006-08-21       Impact factor: 3.441

3.  Cryptosporidium parvum-specific CD4 Th1 cells from sensitized donors responding to both fractionated and recombinant antigenic proteins.

Authors:  Maria Angeles Gomez Morales; Raffaella Mele; Alessandra Ludovisi; Fabrizio Bruschi; Fabio Tosini; Rachele Riganò; Edoardo Pozio
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

4.  Immunostimulatory properties of dendritic cells after Leishmania donovani infection using an in vitro model of liver microenvironment.

Authors:  Ludovic Donaghy; Florian Cabillic; Anne Corlu; Octavie Rostan; Olivier Toutirais; Christiane Guguen-Guillouzo; Claude Guiguen; Jean-Pierre Gangneux
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08

5.  Mycobacterium-Specific γ9δ2 T Cells Mediate Both Pathogen-Inhibitory and CD40 Ligand-Dependent Antigen Presentation Effects Important for Tuberculosis Immunity.

Authors:  Getahun Abate; Charles T Spencer; Fahreta Hamzabegovic; Azra Blazevic; Mei Xia; Daniel F Hoft
Journal:  Infect Immun       Date:  2015-12-07       Impact factor: 3.441

6.  Solute carrier 11A1 is expressed by innate lymphocytes and augments their activation.

Authors:  Jodi F Hedges; Emily Kimmel; Deann T Snyder; Maria Jerome; Mark A Jutila
Journal:  J Immunol       Date:  2013-03-18       Impact factor: 5.422

Review 7.  A diversified role for γδT cells in vector-borne diseases.

Authors:  Chen Chen; Aibao Chen; Yanan Yang
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.